Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.
While the drug demonstrated statistical significance in improving symptoms and exhibited a solid safety profile, the results fell short of the company’s internal bar to prioritize advancement of SPY072 in RA.
Efficacy And Target Engagement
Trial data released on Tuesday indicated that both SPY072 doses successfully hit target drug concentrations. The therapy provided complete, durable suppression of free TL1A through 12 weeks, signaling complete target engagement.
The low dose achieved a statistically significant advantage over a placebo on the primary endpoint, measuring the change from baseline in DAS28-CRP at Week 12.
